Exploring the top 30 drugs associated with drug-induced constipation based on the FDA adverse event reporting system
Frontiers in Pharmacology,
Год журнала:
2024,
Номер
15
Опубликована: Сен. 2, 2024
Objective
This
project
aims
to
identify
the
top
30
drugs
most
commonly
associated
with
constipation
and
their
signal
values
within
FDA
Adverse
Event
Reporting
System
database.
Methods
We
extracted
adverse
drug
events
(ADEs)
related
from
FAERS
database
spanning
January
1,
2004,
September
30,
2023.
compiled
frequently
reported
based
on
frequency
of
events.
employed
detection
methodologies
ascertain
whether
these
elicited
significant
signals,
including
reporting
odds
ratio,
proportional
multi-item
gamma
Poisson
shrinker,
information
component
given
by
Bayesian
confidence
propagation
neural
network.
Furthermore,
we
conducted
a
time-to-onset
(TTO)
analysis
for
generating
signals
using
medians,
quartiles,
Weibull
shape
parameter
test.
Results
total
50,
659,
288
ADEs,
among
which
169,897
(0.34%)
were
constipation.
selected
ranked
drugs.
The
highest
ranking
was
lenalidomide
(7,730
cases,
4.55%),
prevalent
class
being
antineoplastic
immunomodulating
agents.
Signal
performed
drugs,
risk
identified
26
them.
Among
22
exhibited
consistent
those
listed
FDA-approved
labels.
However,
four
(orlistat,
nintedanib,
palbociclib,
dimethyl
fumarate)
presented
an
unexpected
Ranked
values,
sevelamer
carbonate
emerged
as
strongest
[reporting
ratio
(95%
CI):
115.51
(110.14,
121.15);
PRR
(χ
2
):
83.78
(191,709.73);
EBGM
(EB05):
82.63
(79.4);
IC
(IC025):
6.37
(4.70)].
A
TTO
that
generated
revealing
all
early
failure
type.
median
orlistat
3
days,
shortest
while
clozapine
1,065
longest
Conclusion
Our
study
provides
list
potentially
drug-induced
(DIC).
could
inform
clinicians
about
some
alternative
medications
consider
when
managing
secondary
causes
or
caring
patients
prone
DIC,
thereby
reducing
incidence
mortality
DIC.
Язык: Английский
Comparative analysis of cdki-related adverse events in older patients: a real-world data from the FDA adverse event reporting system database
Expert Opinion on Drug Safety,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 19, 2025
Cyclin-dependent
kinase
4
and
6
inhibitors
(CDKIs)
are
effective
safe
against
advanced
metastatic
breast
cancer;
however,
limited
information
is
available
for
older
patients.
We
conducted
an
analysis
of
real-world
data
pertaining
to
the
safety
patients
using
Adverse
Event
Reporting
System
(FAERS)
database
FDA.
performed
a
disproportionality
evaluate
CDKI-related
adverse
events
(AEs)
in
adults
administered
abemaciclib,
palbociclib,
ribociclib.
Data
were
from
2132,
36916,
4328
case
reports
on
ribociclib
patients,
respectively.
Disproportionality
revealed
242,
295,
439
drug-AE
signals.
The
numbers
system
organ
classes
(SOC)
25,
27,
26,
found
several
expected
AE
signals
consistent
with
those
drug
instructions,
such
as
nausea,
neutropenia,
fatigue,
all
CDKIs.
Interstitial
lung
disease,
thromboembolic
events,
cardiac
toxicity
also
noteworthy.
Unexpected
signals,
acute
kidney
injury,
atrial
fibrillation,
memory
impairment
associated
ribociclib,
respectively,
identified.
Our
results
aligned
clinical
observations,
emphasizing
possible
AEs.
Conducting
future
research
essential
confirm
AE-related
differences
among
CDKIs
individuals.
Язык: Английский
Palbociclib as an Antitumor Drug: A License to Kill
Molecules,
Год журнала:
2024,
Номер
29(22), С. 5334 - 5334
Опубликована: Ноя. 13, 2024
Neoplastic
cells
are
characterized
by
uncontrolled
cell
divisions
caused
cycle
dysregulation.
Key
regulatory
proteins
governing
the
transition
from
G1
to
S
phase
CDK4
and
CDK6
kinases,
which
controlled
D-type
cyclins.
The
CDK4/6
kinases
enable
use
of
these
as
targets
for
anticancer
therapy
because
they
prevent
growth
development
malignant
inhibiting
their
activity.
This
paper
surveys
clinical
trial
results
concerning
palbociclib,
first
in-class
FDA-approved
drug
hormone-dependent
breast
cancer.
It
discusses
therapeutic
applications
in
cancer
well
solid
tumors
hematopoietic
malignancies.
Additionally,
presents
an
analysis
palbociclib
resistance
acquired
during
explores
new
approaches,
such
modifications
that
enhance
its
desired
activity
or
open
up
possibilities
(PROTACs).
Язык: Английский
A Prospective Monocentric Study of Invasive Breast Carcinoma Diagnosed at 80 Years and Older: Survival Outcomes and Peculiar Challenges
Cancers,
Год журнала:
2024,
Номер
16(24), С. 4142 - 4142
Опубликована: Дек. 12, 2024
Background:
The
lengthening
of
the
lifespan
led
to
an
increase
in
breast
cancer
(BC)
diagnosed
very
old
age,
but
treatment
recommendations
this
patient
group
usually
lack
evidence-based
practice.
We
conducted
a
prospective
observational
monocentric
study
specifically
targeting
patients
with
invasive
BC
at
80
years
age
or
older.
Methods:
enrolled
88
consecutively
observed
for
new
diagnosis
aim
was
investigate
progression-free
(PFS)
and
overall
survival
(OS),
long
follow-up
period,
along
clinico-pathological
characteristics
population.
Results:
At
end
5-year
follow-up,
estimated
OS
PFS
probabilities
were
82.9%
(95%
CI:
71.3–95.3%)
64.0%
51.7–79.2%),
respectively.
After
8.5
from
diagnosis,
48.9%
died.
cause
death
32.6%
patients,
different
13.9%,
unknown
remaining.
Surgery
performed
69.3%
cases
associated
improved
12-month
(p
<
0.001).
Adjuvant
systemic
therapy
radiotherapy
omitted
32%
93%
eligible
A
higher
rate
metastatic
disease
comparison
data
described
younger
people,
as
well
significantly
high
drop-out
(27.3%).
Conclusions:
Ultra-old
have
not
negligible
life
expectancy;
therefore,
oncologic
should
be
optimal
adequately
fight
BC,
always
considering
quality
these
frail
patients.
Future
research
focus
on
developing
personalized
protocols
that
incorporate
comprehensive
geriatric
assessments
quality-of-life
metrics.
Additionally,
larger,
multicentric
studies
are
needed
validate
our
findings
explore
role
emerging
therapies
group.
Язык: Английский